8QQ Stock Overview
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AbCellera Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.72 |
| 52 Week High | US$7.20 |
| 52 Week Low | US$2.52 |
| Beta | 0.44 |
| 11 Month Change | -27.41% |
| 3 Month Change | -32.29% |
| 1 Year Change | -54.02% |
| 33 Year Change | -84.45% |
| 5 Year Change | n/a |
| Change since IPO | -91.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8QQ | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0.3% | -0.3% | -0.1% |
| 1Y | -54.0% | -16.7% | 2.4% |
Return vs Industry: 8QQ underperformed the German Life Sciences industry which returned -15.9% over the past year.
Return vs Market: 8QQ underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| 8QQ volatility | |
|---|---|
| 8QQ Average Weekly Movement | 7.0% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 8QQ's share price has been volatile over the past 3 months.
Volatility Over Time: 8QQ's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 586 | Carl Hansen | www.abcellera.com |
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
AbCellera Biologics Inc. Fundamentals Summary
| 8QQ fundamental statistics | |
|---|---|
| Market cap | €810.60m |
| Earnings (TTM) | -€136.81m |
| Revenue (TTM) | €33.33m |
22.8x
P/S Ratio-5.6x
P/E RatioIs 8QQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8QQ income statement (TTM) | |
|---|---|
| Revenue | US$35.79m |
| Cost of Revenue | US$162.30m |
| Gross Profit | -US$126.51m |
| Other Expenses | US$20.39m |
| Earnings | -US$146.90m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 06, 2024
| Earnings per share (EPS) | -0.50 |
| Gross Margin | -353.51% |
| Net Profit Margin | -410.48% |
| Debt/Equity Ratio | 0% |
How did 8QQ perform over the long term?
See historical performance and comparison